OR (('high density lipoprotein cholesterol'/exp OR 'low density lipoprotein cholesterol'/exp) AND 'goal attainment'/exp) OR ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C" OR "non HDL C" OR "non-HDL C" OR "non-HDL-C") NEAR/5 (goal OR goals OR target* OR level OR levels)):ti,ab #4 Statins 'hydroxymethylglutaryl coenzyme A reductase inhibitor'/exp OR 'hypocholesterolemic agent'/exp OR ((hydroxymethylglutaryl OR hydroxy-methylglutaryl) NEAR/5 reductase):ti OR (HMG NEXT/1 CoA):ti OR (statin* OR lovastatin OR meglutol OR pravastatin OR atorvastatin OR simvastatin):ti #5 Non-statins 'fibric acid derivative'/exp OR 'gemfibrozil'/exp OR 'hypocholesterolemic agent'/exp OR 'nicotinic acid'/exp OR 'bile acid sequestrant'/exp OR 'ezetimibe'/exp OR 'omega 3 fatty acid'/exp OR (fibrate* OR gemfibrozil OR fenofibrate OR bezafibrate OR (nicotinic NEXT/1 acid*) OR niacin OR ( bile acid NEXT/1 (sequestrant* OR resin*)) OR ezetimibe OR ((omega* OR marine) NEXT/3 fatty) OR pcsk9 OR pcsk-9 OR pcsk 9 OR ((eicosapentaenoic OR docosahexaenoic) NEXT/1 acid*) OR icosapent ethyl OR fish oil ):ti,ab #6 Outcomes of interest 'secondary prevention'/exp OR 'primary prevention'/exp OR 'prevention and control'/exp OR 'treatment outcome'/exp OR 'morbidity'/exp OR 'mortality'/exp OR 'all cause mortality'/exp OR 'cerebrovascular accident'/exp OR 'heart infarction'/exp OR 'unstable angina pectoris'/exp OR (stroke* OR (cerebrovascular NEXT/1 accident*) OR morbidity OR mortality OR death OR (heart NEXT/1 attack*) OR (myocardial NEXT/1 infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) NEXT/2 event*) OR (heart NEXT/1 infarct*)):ti,ab OR (morbidity OR mortality OR prevent* OR outcome*):ti,ab OR (secondary NEXT/1 prevention):ti,ab OR (primary NEXT/1 prevention):ti,ab OR angina:ti,ab OR ('adverse event'/exp OR 'side effect'/exp OR 'safety'/de OR ((side NEXT/1 effect*) OR (adverse NEXT/1 event*) OR safe OR safety)):ti,ab Question Set # Concept Strategy Question Pharmacologic treatment to reach specific LDL-C or non-HDL-C goals (cont.)


analyses Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #10 Apply limits See Search Limits at the end of the table Question Strategies to improve patient tolerance to statins Dyslipidemia dyslipidemia/exp OR 'hypercholesterolemia'/exp OR cholesterol/exp OR lipid/de OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia):ti,ab OR ((high OR elevated OR low) NEAR/5 (cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C")):ti,ab #2 CVD 'cardiovascular disease'/exp/mj/dm_pc OR 'cardiovascular disease'/de OR 'hypertension'/exp OR 'ischemic heart disease'/exp OR 'heart disease'/de OR 'coronary artery disease'/exp OR 'peripheral vascular disease'/exp OR 'cerebral artery disease'/exp OR 'brain ischemia'/exp OR 'cerebrovascular accident'/exp OR 'cerebrovascular disease'/exp OR 'heart infarction'/exp OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) NEAR/5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)):ti,de OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart NEXT/1 attack*) OR (myocardial NEXT/1 infarct*) OR stroke* OR (cerebrovascular tolerance/adheren ce/ substitution (controlled terms) ('hydroxymethylglutaryl coenzyme A reductase inhibitor'/exp OR 'hypocholesterolemic agent'/exp) AND ('medication compliance'/exp OR 'patient compliance'/exp OR 'drug substitution'/exp OR 'drug dose intensification'/exp OR 'drug dose reduction'/exp) #4 Statin tolerance/ adherence/ substitution (keywords) ((hydroxymethylglutaryl or hydroxy-methylglutaryl) NEAR/5 reductase*) OR "HMG CoA" or statin* or lovastatin or meglutol or pravastatin or atorvastatin or simvastatin):ti,ab AND (tolerate* or tolerance or adher* or nonadherence* or non-adherence or ((alternat* or low or lower or high or higher or increase or decrease) NEXT/3 dose or dosing or dosag*)):ti,ab analyses Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #8 Apply limits See Search Limits at the end of this table Question Set # Concept Strategy Questions Pertaining to non-pharmacologic treatment including cost #1 Dyslipidemia dyslipidemia/exp OR 'hypercholesterolemia'/exp OR cholesterol/exp OR lipid/de OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia):ti,ab OR ((high OR elevated OR low) NEAR/5 (cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C")):ti,ab #2 CV risk ('cardiovascular disease'/exp/mj OR 'hypertension'/exp/mj OR 'ischemic heart disease'/exp/mj OR 'heart disease'/mj OR 'coronary artery disease'/exp/mj OR 'peripheral vascular disease'/exp/mj OR 'cerebral artery disease'/exp/mj OR 'brain ischemia'/exp/mj OR 'cerebrovascular accident'/exp/mj OR 'cerebrovascular disease'/exp/mj OR 'heart infarction'/exp/mj OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) NEAR/5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)):ti OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart NEXT/1 attack*) OR (myocardial NEXT/1 infarct*) OR stroke* OR (cerebrovascular NEXT/1 accident*)):ti) AND (risk* OR prevent*):ti supplements/ neutraceuticals 'dietary supplement'/exp OR 'plant medicinal product'/exp OR 'omega 3 fatty acid'/exp OR 'vitamin'/de OR garlic/exp OR 'dietary fiber'/exp OR 'ginger'/exp OR 'phytosterol'/exp OR 'ispagula'/exp OR 'tea'/exp OR (((diet OR dietary) NEAR/5 supplement*) OR neutraceutical* OR ((omega* OR marine) NEXT/3 fatty) or "fish oil" OR ((eicosapentaenoic OR docosahexaenoic) NEXT/1 acid*) OR icosapent ethyl OR ((diet* OR soluable) NEAR/5 fiber) OR garlic OR ginger OR phytosterol* OR (plant NEXT/2 sterol*) OR (green NEXT/1 tea*) OR niacin* OR psyllium):ti #4 Diet therapy 'diet therapy'/exp OR ((Diet or diets or dietary or nutrition) and ("low sodium" or "low fat" or (gluten next/2 free) or "low gluten" or "low carb" or "low carbohydrate" or "low calorie" or vegetarian or vegan or macrobiotic or Mediterranean or DASH)):ti or "diabetic diet":ti or (dietary next/1 approach* NEXT/1 stop NEXT/1 hypertension):ti or diet*:ti #5 Exercise 'exercise'/exp OR (aerobics OR dance OR dancing OR exercise* OR fitness OR kinesiotherapy OR "muscle strengthening" OR "physical activity" OR "physical conditioning" OR "plyometric training" OR "resistance training" OR "strength training" OR "tai chi" OR "tai-chi" OR walk* OR "weight lifting" OR yoga OR swim OR swimming OR run OR running OR "weight training"):ti #6 Outcomes of interest 'secondary prevention'/exp OR 'primary prevention'/exp OR 'prevention and control'/exp OR 'treatment outcome'/exp OR 'morbidity'/exp OR 'mortality'/exp OR 'all cause mortality'/exp OR 'cerebrovascular accident'/exp OR 'heart infarction'/exp OR 'unstable angina pectoris'/exp OR (stroke* OR (cerebrovascular NEXT/1 accident*) OR morbidity OR mortality OR death OR (heart NEXT/1 attack*) OR (myocardial NEXT/1 infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) NEXT/2 event*) OR (heart NEXT/1 infarct*)):ti,ab OR (morbidity OR mortality OR prevent* OR outcome*):ti,ab OR (secondary NEXT/1 prevention):ti,ab OR (primary NEXT/1 prevention):ti,ab OR angina:ti,ab OR ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C") AND (level OR levels OR lower OR low OR reduce OR reduction OR profile*)):ti,ab OR ('adverse event'/exp OR 'side effect'/exp OR 'safety'/de OR ((side NEXT/1 effect*) OR (adverse NEXT/1 event*) OR safe OR safety):ti,ab #7 Combine sets including outcomes of interest Question Set # Concept Strategy Questions Pertaining to non-pharmacologic treatment including cost (cont.)


#8 Combine sets without outcomes of interest #9 Limit to RCTs Randomized controlled trials hedge [see Search Limits at the end of this table] #10 Limit to SRs/Meta- analysis Systematic review/meta-analysis hedge [see Search Limits at the end of this table] #11 Limit to cost studies (KQ 9) 'health care cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit analysis'/exp OR 'economic evaluation'/exp OR 'quality adjusted life year'/exp OR (cost OR costs OR costly OR costing OR price OR prices OR saving OR savings OR economi* OR financial OR finance* OR pharmacoeconomic* OR QALY or QALYs OR (quality NEXT/1 adjusted NEXT/1 life NEXT/1 year*) or (quality NEXT/1 adjusted life NEXT/1 expectanc*)):ti,ab #15 Apply limits See Search Limits at the end of this table Search Limits Applied to Each Search Limit to humans and items published since searches were conducted for AND [humans]/lim AND [english]/lim AND [9-12-2013]/sd NOT [2019]/sd Exclude conference publications, books, letters, editorials, case studies, etc.


(abstract:nc OR annual:nc OR book/de OR 'case report'/de OR 'case study'/de OR conference:nc OR 'conference abstract':it OR 'conference paper'/de OR 'conference paper':it OR 'conference proceeding':pt OR 'conference review':it OR congress:nc OR editorial/de OR editorial:it OR erratum/de OR letter:it OR note/de OR note:it OR meeting:nc OR sessions:nc OR 'short survey'/de OR symposium:nc) Limit to meta- analyses and SRs AND ('systematic review'/exp OR 'systematic review' OR 'meta analysis'/exp OR 'meta analysis') Limit to RCTs ('randomized controlled trial'/exp OR 'randomization'/de OR 'double blind procedure'/de OR 'single blind procedure'/de OR 'placebo'/de OR 'crossover procedure'/de OR placebo* OR random*:ti,de OR crossover* OR 'cross over' OR ((singl* OR doubl* OR tripl* OR trebl*) AND (blind* OR mask* OR sham*)) OR 'latin square' OR isrtcn* OR actrn* OR (nct* NOT nct)) B. MEDLINE with Ovid Syntax Question Set # Concept Strategy Question Time to repeat screening for CV risk (Note: this search builds upon the search for Questions and which include specific terms for CV risk) #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. assessment mass screening/ or exp multiphasic screening/ OR risk assessment/ OR ((risk or risks) ADJ4 (stratify or stratifying or stratification or define or defining or predict or prediction or assess* OR classif* OR prioritiz* OR category* OR tier* OR calculat* OR index OR indices OR score OR scores OR marker* OR biomarker* OR profile* OR algorithm* OR factor* OR characteristic*)).ti,ab.


assessment mass screening/ or exp multiphasic screening/ OR risk assessment/ OR ((risk or risks) ADJ4 (stratify or stratifying or stratification or define or defining or predict or prediction or assess* OR classif* OR prioritiz* OR category* OR tier* OR calculat* OR index OR indices OR score OR scores OR marker* OR biomarker* OR profile* OR algorithm* OR factor* OR characteristic*)).ti,ab. OR (cardiovascular ADJ2 risk*) #3 Repeat screening/ monitoring Exp time factors/ OR Monitoring, Physiologic/ OR (rescreen* OR re-screen* OR surveillance OR re-assess* OR monitor* OR ((repeat or repet* or replicat* or redo or "re-do" or rerun or "re-run" or subsequent* or redundant* or re-assess* or reassess*OR "follow up" OR "follow-up") ADJ4 (test* or screen* OR assess*))).ti,ab. #4 Outcomes exp *Cardiovascular Diseases/pc OR exp primary prevention/ OR exp mortality/ OR exp morbidity/ OR exp death/ OR exp myocardial infarction/ OR cerebrovascular accident/ OR stroke/ OR exp Angina, Unstable/ OR (stroke* OR (cerebrovascular ADJ accident*) OR morbidity OR mortality OR death OR (heart ADJ attack*) OR (myocardial ADJ infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) ADJ2 event*) OR (heart ADJ infarct*)).ti,ab. OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab. OR angina.ti,ab.


OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab. OR angina.ti,ab. #6 Limit to RCTs/SRs/ Meta-analysis Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #7 Limit to additional study designs exp cohort studies/ OR exp longitudinal studies/ OR exp retrospective studies/ OR exp prospective studies OR exp controlled study/ or exp clinical trial/ or exp comparative study/ OR major clinical study/ OR cross-over studies/ or crossover procedure/ or cross over studies/ OR observational study/ OR validation studies/ OR exp case-control studies/ OR follow-up studies/ #9 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Stability of lipid levels over time #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. #2 CVD exp *Cardiovascular Diseases/pc or cardiovascular diseases/ or heart diseases/ or vascular diseases/ or exp arterial occlusive diseases/ or cerebrovascular disorders/ or exp brain ischemia/ or exp stroke/ or exp myocardial ischemia/ or exp myocardial Infarction/ or exp heart arrest/ or exp hypertension/ or exp peripheral vascular diseases/ or ((heart* or cardio* or cardiac* or coronary or vascular or cerebrovascular or artery or arteries) ADJ5 (disease* or syndrome* or event* or ischem* or ischaem* or plaque*)).ti,ab. or (hyperten* or atherosclero* or arteriosclero* or angina or (Heart ADJ attack*) or (myocardial ADJ infarct*) or stroke* or (cerebrovascular ADJ accident*)).ti,ab.


or (hyperten* or atherosclero* or arteriosclero* or angina or (Heart ADJ attack*) or (myocardial ADJ infarct*) or stroke* or (cerebrovascular ADJ accident*)).ti,ab. #3 Monitoring of lipid levels over time (Lipids/an,bl,td OR exp Cholesterol/an,bl,td) AND (Exp Monitoring, physiologic/ OR exp lipid analysis/ OR exp lipid metabolism/ OR Exp time factors/) OR ((cholesteryl* or cholesterol* or lipid* or lipoprotein* or tryglycer* or triaclyglycer* or "HDL-C" or "LDL-C" or "HDL C" or "LDL C" or "non HDL C" or "non-HDL C" or "non-HDL-C") ADJ5 (level or levels or blood OR value*) ADJ5 (monitor* OR surveillance OR stable OR stability OR variability OR variable OR "long term" OR "long- term" OR longitud* OR trend*)).ti,ab. #5 Limit to RCTs/SRs/ Meta-analysis Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #6 Limit to additional study designs exp cohort studies/ OR exp longitudinal studies/ OR exp retrospective studies/ OR exp prospective studies OR exp controlled study/ or exp clinical trial/ or exp comparative study/ OR major clinical study/ OR cross-over studies/ or crossover procedure/ or cross over studies/ OR observational study/ OR validation studies/ OR exp case-control studies/ #8 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Methods for risk stratification #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab.


#5 Limit to RCTs/SRs/ Meta-analysis Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #6 Limit to additional study designs exp cohort studies/ OR exp longitudinal studies/ OR exp retrospective studies/ OR exp prospective studies OR exp controlled study/ or exp clinical trial/ or exp comparative study/ OR major clinical study/ OR cross-over studies/ or crossover procedure/ or cross over studies/ OR observational study/ OR validation studies/ OR exp case-control studies/ #8 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Methods for risk stratification #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. #2 CVD exp *Cardiovascular Diseases/ OR *heart diseases/ or *vascular diseases/ or exp *arterial occlusive diseases/ or *cerebrovascular disorders/ OR exp *brain ischemia/ or exp *stroke/ or exp *myocardial ischemia/ OR exp *myocardial Infarction/ OR exp *heart arrest/ OR exp *hypertension/ OR exp *peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti. OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti.


OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti. prediction/stratifica tion exp *risk factors/ OR exp*risk assessment/ OR ((risk or risks) ADJ4 (stratify or stratifying or stratification or define or defining or predict or prediction or assessment OR classif* OR prioritiz* OR category* OR tier* OR calculat* OR index OR indices OR score OR scores OR marker* OR biomarker* OR profile* OR algorithm* OR factor* OR characteristic*)).ti. OR (cardiovascular ADJ2 risk*).ti. #4 Risk stratification tools Lipids/an,bl OR exp Cholesterol/an,bl OR exp Ankle Brachial Index/ OR exp Galectin 3/ OR C-Reactive Protein/ OR exp Apolipoproteins B/ OR exp Carotid Intima-Media Thickness/ OR c-reactive protein/ or exp Troponin I/ OR ((framingham ADJ2 risk*) OR 'ankle brachial index' OR (coronary ADJ2 calcium) OR ('c reactive' ADJ2 protein*) OR 'hs-crp' OR 'hs crp' OR 'hscrp' OR 'ntprobnp' OR 'nt-probnp' OR 'hs-tnl' OR 'hs tnl' OR 'galecton 3' OR 'galecton-3' OR 'pooled cohort' OR (particle ADJ2 size*) OR (high ADJ sensitiv* ADJ troponin*) OR apolipoprotein* OR lipoprotein* OR (carotid ADJ1 intima* ADJ3 thickness*)).ti,ab. OR ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C" OR "non HDL C" OR "non-HDL C" OR "non-HDL-C") ADJ5 (level OR levels)).ti. #5 Outcomes of interest exp *Cardiovascular Diseases/pc OR exp primary prevention/ OR exp mortality/ OR exp morbidity/ OR exp death/ OR exp myocardial infarction/ OR cerebrovascular accident/ OR stroke/ OR exp Angina, Unstable/ OR (stroke* OR (cerebrovascular ADJ accident*) OR morbidity OR mortality OR death OR (heart ADJ attack*) OR (myocardial ADJ infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) ADJ2 event*) OR (heart ADJ infarct*)).ti,ab. OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab.


OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab. OR angina.ti,ab. #6 Combine sets dyslipidemia terms plus CV outcomes #7 Combine sets CV terms without the outcomes string #9 Limit to RCTs/SRs/Meta- analysis Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] Question Set # Concept Strategy Question Methods for risk stratification (cont.) #10 Limit to additional study designs exp cohort studies/ OR exp longitudinal studies/ OR exp retrospective studies/ OR exp prospective studies OR exp controlled study/ or exp clinical trial/ or exp comparative study/ OR major clinical study/ OR cross-over studies/ or crossover procedure/ or cross over studies/ OR observational study/ OR validation studies/ OR exp case-control studies/ti #11 Diagnostic test hedge exp diagnosis/ or di.fs. or receiver operating characteristic/ or ROC curve/ or (sensitivity/ and specificity/) or accuracy/ or diagnostic accuracy/ or precision or (prediction and forecasting) or likelihood or ((false or true) ADJ (positive or negative)) or predictive value of tests/ or exp diagnostic errors/ or exp diagnostic error/ or diagnostic accuracy/ or positive predictive value or PPV OR (predictive value of tests or receiver operating characteristic or ROC curve or (sensitivity and specificity) or accuracy or diagnostic accuracy or precision or likelihood).de. OR ((false or true) ADJ (positive or negative)).mp. #13 Apply limits See Search Limits at the end of the table Questions Pertaining to pharmacologic treatment including cost #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR exp lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab.


#13 Apply limits See Search Limits at the end of the table Questions Pertaining to pharmacologic treatment including cost #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR exp lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. #2 CVD exp *Cardiovascular Diseases/pc OR cardiovascular diseases/ or heart diseases/ or vascular diseases/ or exp arterial occlusive diseases/ or cerebrovascular disorders/ OR exp brain ischemia/ or exp stroke/ or exp myocardial ischemia/ OR exp myocardial Infarction/ OR exp heart arrest/ OR exp hypertension/ OR exp peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti,ab. OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti,ab. treatments: statins exp Hypolipidemic Agents/ or exp Ezetimibe, Simvastatin Drug Combination/ or exp Anticholesteremic Agents/ or exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ or ((hydroxymethylglutaryl or hydroxy-methylglutaryl) ADJ5 (reductase ADJ inhibitor*)).ti. or "HMG CoA".ti. or (statin* or lovastatin or meglutol or pravastatin or atorvastatin or simvastatin).ti. treatments: non- statins Gemfibrozil/ or fenofibrate/ or niacin/ or exp Fatty Acids, Omega-3/ or exp Ezetimibe/ or exp Proprotein Convertase 9/tu or exp "Bile Acids and Salts"/tu OR (fibrate* or gemfibrozil or fenofibrate or bezafibrate or (nicotinic adj acid*) or niacin or (bile ADJ acid ADJ sequestrant*) or (bile ADJ acid ADJ resin*) or ezetimibe or (omega* ADJ3 fatty adj acid*) or "fish oil" or pcsk9 or pcsk-9 or "pcsk 9" or ((eicosapentaenoic or docosahexaenoic) ADJ acid*)).ti,ab.


treatments: non- statins Gemfibrozil/ or fenofibrate/ or niacin/ or exp Fatty Acids, Omega-3/ or exp Ezetimibe/ or exp Proprotein Convertase 9/tu or exp "Bile Acids and Salts"/tu OR (fibrate* or gemfibrozil or fenofibrate or bezafibrate or (nicotinic adj acid*) or niacin or (bile ADJ acid ADJ sequestrant*) or (bile ADJ acid ADJ resin*) or ezetimibe or (omega* ADJ3 fatty adj acid*) or "fish oil" or pcsk9 or pcsk-9 or "pcsk 9" or ((eicosapentaenoic or docosahexaenoic) ADJ acid*)).ti,ab. Question Set # Concept Strategy Questions Pertaining to pharmacologic treatment including cost (cont.) #5 Outcomes of interest Exp secondary prevention/ OR exp primary prevention/ OR exp mortality/ OR exp morbidity/ OR exp death/ OR exp myocardial infarction/ OR cerebrovascular accident/ OR stroke/ OR exp Angina, Unstable/ OR (stroke* OR (cerebrovascular ADJ accident*) OR morbidity OR mortality OR death OR (heart ADJ attack*) OR (myocardial ADJ infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) ADJ2 event*) OR (heart ADJ infarct*)).ti,ab. OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab. OR angina.ti,ab. OR ae.fs.OR to.fs. OR safety/ or exp patient harm/ OR ((side ADJ effect*) OR (adverse ADJ event*) OR safe OR safety).ti,ab. Additional outcome of interest for KQ 8 [change in lipid levels] ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C") AND (level OR levels OR lower OR low OR reduce OR reduction OR profile* OR target*)).ti,ab.


Additional outcome of interest for KQ 8 [change in lipid levels] ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C") AND (level OR levels OR lower OR low OR reduce OR reduction OR profile* OR target*)).ti,ab. #6 Combine sets including outcomes of interest #7 Combine sets without outcomes of interest #8 Limit to RCTs Randomized controlled trials hedge [see Search Limits at the end of this table] #9 Limit to SRs/Meta- analyses Systematic review/meta-analysis hedge [see Search Limits at the end of this table] #10 Limit to cost studies 'health care cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit analysis'/exp OR 'economic evaluation'/exp OR 'quality adjusted life year'/exp OR (cost OR costs OR costly OR costing OR price OR prices OR saving OR savings OR economi* OR financial OR finance* OR pharmacoeconomic* OR QALY or QALYs OR (quality NEXT/1 adjusted NEXT/1 life NEXT/1 year*) or (quality NEXT/1 adjusted life NEXT/1 expectanc*)):ti,ab #14 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Pharmacologic treatment to reach specific LDL-C or non-HDL-C goals #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR ((high OR elevated OR low) ADJ5 (cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C"))).ti,ab.


#6 Combine sets including outcomes of interest #7 Combine sets without outcomes of interest #8 Limit to RCTs Randomized controlled trials hedge [see Search Limits at the end of this table] #9 Limit to SRs/Meta- analyses Systematic review/meta-analysis hedge [see Search Limits at the end of this table] #10 Limit to cost studies 'health care cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit analysis'/exp OR 'economic evaluation'/exp OR 'quality adjusted life year'/exp OR (cost OR costs OR costly OR costing OR price OR prices OR saving OR savings OR economi* OR financial OR finance* OR pharmacoeconomic* OR QALY or QALYs OR (quality NEXT/1 adjusted NEXT/1 life NEXT/1 year*) or (quality NEXT/1 adjusted life NEXT/1 expectanc*)):ti,ab #14 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Pharmacologic treatment to reach specific LDL-C or non-HDL-C goals #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR ((high OR elevated OR low) ADJ5 (cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C"))).ti,ab. #2 CVD exp *Cardiovascular Diseases/pc OR cardiovascular diseases/ or heart diseases/ or vascular diseases/ or exp arterial occlusive diseases/ or cerebrovascular disorders/ OR exp brain ischemia/ or exp stroke/ or exp myocardial ischemia/ OR exp myocardial Infarction/ OR exp heart arrest/ OR exp hypertension/ OR exp peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti,ab.


#2 CVD exp *Cardiovascular Diseases/pc OR cardiovascular diseases/ or heart diseases/ or vascular diseases/ or exp arterial occlusive diseases/ or cerebrovascular disorders/ OR exp brain ischemia/ or exp stroke/ or exp myocardial ischemia/ OR exp myocardial Infarction/ OR exp heart arrest/ OR exp hypertension/ OR exp peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti,ab. OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti,ab. #3 LDL-C or non-HDL-C goals (exp Cholesterol, HDL/bl OR exp Cholesterol, LDL/bl OR exp lipids/bl OR exp cholesterol/bl) AND (goal OR goals OR target* OR level OR levels).ti. OR ((exp Cholesterol, HDL/ OR exp Cholesterol, LDL/ OR exp lipids/ OR exp cholesterol/) AND exp goals/) OR ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C" OR "non HDL C" OR "non-HDL C" OR "non-HDL-C") ADJ5 (goal OR goals OR target* OR level OR levels)).ti,ab. #4 Statins exp Hypolipidemic Agents/ or exp Ezetimibe, Simvastatin Drug Combination/ or exp Anticholesteremic Agents/ or exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ or ((hydroxymethylglutaryl or hydroxy-methylglutaryl) ADJ5 (reductase ADJ inhibitor*)).ti. or "HMG CoA".ti. or (statin* or lovastatin or meglutol or pravastatin or atorvastatin or simvastatin).ti.


or (statin* or lovastatin or meglutol or pravastatin or atorvastatin or simvastatin).ti. #5 Non-statins Gemfibrozil/ or fenofibrate/ or niacin/ or exp Fatty Acids, Omega-3/ or exp Ezetimibe/ or exp Proprotein Convertase 9/tu or exp "Bile Acids and Salts"/tu OR (fibrate* or gemfibrozil or fenofibrate or bezafibrate or (nicotinic ADJ acid*) or niacin or (bile ADJ acid ADJ sequestrant*) or (bile ADJ acid ADJ resin*) or ezetimibe or (omega* ADJ3 fatty adj acid*) or "fish oil" or pcsk9 or pcsk-9 or "pcsk 9" or ((eicosapentaenoic or docosahexaenoic) ADJ acid*)).ti,ab. #6 Outcomes of interest Exp secondary prevention/ OR exp primary prevention/ OR exp mortality/ OR exp morbidity/ OR exp death/ OR exp myocardial infarction/ OR cerebrovascular accident/ OR stroke/ OR exp Angina, Unstable/ OR (stroke* OR (cerebrovascular ADJ accident*) OR morbidity OR mortality OR death OR (heart ADJ attack*) OR (myocardial ADJ infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) ADJ2 event*) OR (heart ADJ infarct*)).ti,ab. OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab. OR angina.ti,ab. OR ae.fs.OR to.fs. OR safety/ or exp patient harm/ OR ((side ADJ effect*) OR (adverse ADJ event*) OR safe OR safety).ti,ab. analyses Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #10 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Strategies to improve patient tolerance to statins #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR exp lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab.


analyses Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #10 Apply limits See Search Limits at the end of the table Question Set # Concept Strategy Question Strategies to improve patient tolerance to statins #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR exp lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. #2 CVD exp *Cardiovascular Diseases/pc OR cardiovascular diseases/ or heart diseases/ or vascular diseases/ or exp arterial occlusive diseases/ or cerebrovascular disorders/ OR exp brain ischemia/ or exp stroke/ or exp myocardial ischemia/ OR exp myocardial Infarction/ OR exp heart arrest/ OR exp hypertension/ OR exp peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti,ab. OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti,ab. tolerance/adherenc e/ substitution (controlled terms) (exp Hypolipidemic Agents/ or exp Ezetimibe, Simvastatin Drug Combination/ or exp Anticholesteremic Agents/ or exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/) AND (exp Medication Adherence/ or exp "Treatment Adherence and Compliance"/ OR exp Drug Substitution/ OR exp Drug Administration Schedule/) tolerance/adherenc e/ substitution (keywords) (((hydroxymethylglutaryl or hydroxy-methylglutaryl) ADJ5 (reductase ADJ inhibitor*)) OR "HMG CoA" or statin* or lovastatin or meglutol or pravastatin or atorvastatin or simvastatin).ti,ab. AND (tolerate* or tolerance or adher* or nonadherence* or non-adherence or ((alternat* or low or lower or high or higher or increase or decrease) ADJ3 dose or dosing or dosag*)).ti,ab.


AND (tolerate* or tolerance or adher* or nonadherence* or non-adherence or ((alternat* or low or lower or high or higher or increase or decrease) ADJ3 dose or dosing or dosag*)).ti,ab. analyses Randomized controlled trials/systematic review/meta-analysis hedge [see Search Limits at the end of this table] #8 Apply limits See Search Limits at the end of this table Question Set # Concept Strategy Questions Pertaining to non-pharmacologic treatment including cost #1 Dyslipidemia exp dyslipidemias/ OR exp cholesterol/ OR lipids/ OR (dyslipidemia* OR dyslipidaemia* OR dyslipidproteinemia* OR dyslipidproteinaemia* OR hyperlipidemia* OR hyperlipidaemia* OR hypercholesterolemia* OR hypercholesterolaemia* OR hyperlipoproteinemia* OR hyperlipoproteinaemia* OR hypertriglyceridemia* OR hypertriglyceridaemia* OR hyperlipemia OR hyperlipaemia OR cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C").ti,ab. #2 CV risk (exp *Cardiovascular Diseases/ OR *heart diseases/ or *vascular diseases/ or exp *arterial occlusive diseases/ or *cerebrovascular disorders/ OR exp *brain ischemia/ or exp *stroke/ or exp *myocardial ischemia/ OR exp *myocardial Infarction/ OR exp *heart arrest/ OR exp *hypertension/ OR exp *peripheral vascular diseases/ OR ((heart* OR cardio* OR cardiac* OR coronary OR vascular OR cerebrovascular OR artery OR arteries) ADJ5 (disease* OR syndrome* OR event* OR ischem* OR ischaem* OR plaque*)).ti. OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti.) AND (prevent* OR risk*).ti.


OR (hyperten* OR atherosclero* OR arteriosclero* OR angina OR (Heart ADJ attack*) OR (myocardial ADJ infarct*) OR stroke* OR (cerebrovascular ADJ accident*)).ti.) AND (prevent* OR risk*).ti. supplements/ neutraceuticals exp dietary supplements/ OR exp herbal medicine/ OR exp plants, Medicinal/ OR vitamins/ OR exp plant extracts/ OR exp Fatty Acids, Omega-3/ or exp garlic/tu OR exp Dietary Fiber/tu OR exp psyllium/tu OR exp ginger/tu OR exp phytosterols/ OR exp tea/ or exp teas, herbal/ OR exp niacin/tu OR (((diet OR dietary) ADJ5 supplement*) OR neutraceutical* OR (omega* ADJ3 fatty ADJ acid*) or "fish oil" or ((eicosapentaenoic or docosahexaenoic) ADJ acid*) OR ((diet* OR soluable) ADJ5 fiber) OR garlic OR ginger OR phytosterol* OR (plant ADJ2 sterol*) OR (green ADJ tea*) OR niacin* OR psyllium).ti. #4 Diet therapy exp Diet Therapy/ or ((Diet or diets or dietary or nutrition) and ("low sodium" or "low fat" or (gluten ADJ2 free) or "low gluten" or "low carb" or "low carbohydrate" or "low calorie" or vegetarian or vegan or macrobiotic or Mediterranean or DASH)).ti. or "diabetic diet".mp. or (dietary ADJ approaches ADJ1 stop ADJ hypertension).ti. or diet*.ti. #5 Exercise exp Exercise/ OR exp Resistance Training/ OR (aerobics OR dance OR dancing OR exercise* OR fitness OR kinesiotherapy OR muscle strengthening OR physical activity OR physical conditioning OR plyometric training OR resistance training OR strength training OR tai chi OR walk* OR weight lifting OR yoga OR swim OR swimming OR run OR running OR weight training).ti.


#5 Exercise exp Exercise/ OR exp Resistance Training/ OR (aerobics OR dance OR dancing OR exercise* OR fitness OR kinesiotherapy OR muscle strengthening OR physical activity OR physical conditioning OR plyometric training OR resistance training OR strength training OR tai chi OR walk* OR weight lifting OR yoga OR swim OR swimming OR run OR running OR weight training).ti. #6 Outcomes of interest exp *Cardiovascular Diseases/pc OR Exp secondary prevention/ OR exp primary prevention/ OR exp mortality/ OR exp morbidity/ OR exp death/ OR exp myocardial infarction/ OR cerebrovascular accident/ OR stroke/ OR exp Angina, Unstable/ OR (stroke* OR (cerebrovascular ADJ accident*) OR morbidity OR mortality OR death OR (heart ADJ attack*) OR (myocardial ADJ infarct*) OR ((vascular OR cardiac OR coronary OR cerebrovascular) ADJ2 event*) OR (heart ADJ infarct*)).ti,ab. OR (morbidity OR mortality OR prevent* OR outcome*).ti,ab. OR (secondary ADJ prevention).ti,ab. OR (primary ADJ prevention).ti,ab.OR ((cholesteryl* OR cholesterol* OR lipid* OR lipoprotein* OR tryglycer* OR triaclyglycer* OR "HDL-C" OR "LDL-C" OR "HDL C" OR "LDL C") AND (level OR levels OR lower OR low OR reduce OR reduction OR profile* OR target*)).ti,ab. OR angina.ti,ab. OR ae.fs.OR to.fs. OR safety/ or exp patient harm/ OR ((side ADJ effect*) OR (adverse ADJ event*) OR safe OR safety).ti,ab. #7 Combine sets including outcomes of interest Question Set # Concept Strategy Questions Pertaining to non-pharmacologic treatment including cost (cont.)


#7 Combine sets including outcomes of interest Question Set # Concept Strategy Questions Pertaining to non-pharmacologic treatment including cost (cont.) #8 Combine sets without outcomes of interest #9 Limit to RCTs Randomized controlled trials hedge [see Search Limits at the end of this table] #10 Limit to SRs/Meta- analysis Systematic review/meta-analysis hedge [see Search Limits at the end of this table] #11 Limit to cost studies 'health care cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit analysis'/exp OR 'economic evaluation'/exp OR 'quality adjusted life year'/exp OR (cost OR costs OR costly OR costing OR price OR prices OR saving OR savings OR economi* OR financial OR finance* OR pharmacoeconomic* OR QALY or QALYs OR (quality NEXT/1 adjusted NEXT/1 life NEXT/1 year*) or (quality NEXT/1 adjusted life NEXT/1 expectanc*)):ti,ab #15 Apply limits See Search Limits at the end of this table Search Limits Applied to Each Search Limit to humans and items published since searches were conducted for 2014 CPG AND (english language and humans); limit 18 to ed=20131209-2019 Exclude conference publications, books, letters, editorials, case studies, etc. NOT ("column/opinion" OR "comment/reply" OR dissertation OR editorial OR letter OR book).dt. OR book.pt. OR letter/ or editorial/ or news/ or comment/ or case report or case reports/ or note/ or conference paper/ or (letter or editorial or news or comment or case reports or conference abstract*).pt. OR (child* or teen* or adolescen* or school* or baby or babies or infant* or neonat* or pediatric* or kid or kids or preschool*).ti. Limit to meta- analyses and SRs AND ('systematic review'/exp OR 'systematic review' OR 'meta analysis'/exp OR 'meta analysis') Limit to RCTs AND (Randomized controlled trials or random allocation or double-blind method or single-blind method or placebos or cross-over studies).de. or placebo*.mp. or random*.ti. or randomized controlled trial.pt. OR crossover*.mp. or cross over.mp.


or random*.ti. or randomized controlled trial.pt. OR crossover*.mp. or cross over.mp. or ((singl* or doubl* or tripl* or trebl*) ADJ3 (blind* or mask* or sham*)).mp. or latin square.mp. or ISRTCN or ACTRN* or (NCT* not NCT) or (clinical trials/ and random*.ti.) Appendix K: Alternative Text Description of Algorithm The following outline narratively describes the Algorithm: Management of Dyslipidemia for Cardiovascular Risk Reduction. An explanation of the purpose of the algorithms and description of the various shapes used within the algorithms can be found in the Algorithm background section. The sidebars referenced within this outline can also be found in the Algorithm background section. Algorithm: Management of Dyslipidemia for Cardiovascular Risk Reduction 1. Module A begins with Box 1, in the shape of a rounded rectangle: Patient 40 years old (There are no evidence-based recommendations for patients under age 40 because there is no evidence for the benefit of lipid screening and treatment within this age group. In patients younger than 40 years old interested in pursuing lipid testing and management, shared decision making is recommended to discuss the risks and unknown benefit of pharmacotherapy, with therapeutic lifestyle changes being the primary focus of CVD primary prevention.) 2. Box 1 connects to Box 2, in the shape of a hexagon, asks the question: Does patient have HF with EF <35%, ESRD, or life expectancy <5 years? a. If the answer is Yes to Box 2, then Box 3, in the shape of an oval: Discuss lack of evidence demonstrating benefit and continue ongoing care b. If the answer is No to Box 2, then Box 4, in the shape of a hexagon, asks the question: Does patient have higher risk CVD? (see Sidebar 2) i.


If the answer is No to Box 2, then Box 4, in the shape of a hexagon, asks the question: Does patient have higher risk CVD? (see Sidebar 2) i. If the answer is Yes to Box 4, then Box 5, in the shape of a rectangle: Recommend stepped intensification: 1. Maximize statin or add ezetimibe 2. Consider PCSK9 inhibitor only after maximizing statin and adding ezetimibe 1) Box 5 connects to Box 10, in the shape of a rectangle: If MI, ACS, or CABG/PCI in past 6 weeks, refer for cardiac rehab 2) Box 10 connects to Box 11, in the shape of a rectangle: Recommend dietitian-led Mediterranean diet for risk >12% 3) Box 11 connects to Box 12, in the shape of a rectangle: Recommend regular aerobic exercise(Suggest regular aerobic activity of any intensity or duration. Although incremental benefit is associated with increased doses of physical activity, lower doses including leisure time activity [i.e., walking, landscaping, washing dishes] are associated with benefit when compared to mostly sedentary behavior. A provider s considerations when recommending physical activity might include a patient s motivation, functional capacity, and physical activity preferences.) and smoking cessation (if applicable) 4) Box 12 connects to Box 13, in the shape of a rectangle: Follow up evaluation: 1. Primary prevention, no statin: Lipids every 10 years, recommend non- fasting; Repeat risk evaluation at Box 1: Every 2 years if 6 12%, Every 5 years if <6%, If risk factors change. 2. Secondary prevention: lipids as needed only if higher risk and willing to intensify; 3. Once on optimal therapy, no need to recheck lipids routinely ii.


Once on optimal therapy, no need to recheck lipids routinely ii. If the answer is No to Box 4, then Box 6, in the shape of a hexagon, asks the question: Does patient have CVD per Sidebar 1, DM, or LDL 190 mg/dL? 1) If the answer is Yes to Box 6, then Box 7, in the shape of a rectangle: Recommend moderate-dose statin (see Sidebar 3) 2) If the answer is No to Box 6, then Box 8, in the shape of a hexagon, asks the question: Is patient s 10-year CVD risk >12%? a) If the answer is Yes to Box 8, then Box 7, in the shape of a rectangle: Recommend moderate-dose statin (see Sidebar 3) b) If the answer is No to Box 8, then Box 9, in the shape of a hexagon, asks the question: Is patient s 10-year risk 6 12% and does patient prefer statin treatment? i) If the answer is Yes to Box 9, then Box 7, in the shape of a rectangle: Recommend moderate-dose statin (see ii) If the answer is No to Box 9, then Box 12, in the shape of a rectangle: Recommend regular aerobic exercise (Suggest regular aerobic activity of any intensity or duration. Although incremental benefit is associated with increased doses of physical activity, lower doses including leisure time activity [i.e., walking, landscaping, washing dishes] are associated with benefit when compared to mostly sedentary behavior. A provider s considerations when recommending physical activity might include a patient s motivation, functional capacity, and physical activity preferences.) and smoking cessation (if applicable) (1) Box 12 connects to Box 13, in the shape of a rectangle: Follow up evaluation: 1. Primary prevention, no statin: Lipids every 10 years, recommend non-fasting; Repeat risk evaluation at If risk factors change. 2.


Primary prevention, no statin: Lipids every 10 years, recommend non-fasting; Repeat risk evaluation at If risk factors change. 2. Secondary prevention: lipids as needed only if higher risk and willing to intensify; 3. Once on optimal therapy, no need to recheck lipids routinely 3. Box 7 connects to Box 11, in the shape of a rectangle: Recommend dietitian-led Mediterranean diet for risk >12% 4. Box 11 connects to Box 12, in the shape of a rectangle: Recommend regular aerobic exercise (Suggest regular aerobic activity of any intensity or duration. Although incremental benefit is associated with increased doses of physical activity, lower doses including leisure time activity [i.e., walking, landscaping, washing dishes] are associated with benefit when compared to mostly sedentary behavior. A provider s considerations when recommending physical activity might include a patient s motivation, functional capacity, and physical activity preferences.) and smoking cessation (if applicable) 5. Box 12 connects to Box 13, in the shape of a rectangle: Follow up evaluation: 1. Primary prevention, no statin: Lipids every 10 years, recommend non-fasting; Repeat risk evaluation at Box 1: Every 2 years if 6 12%, Every 5 years if <6%, If risk factors change. 2. Secondary prevention: lipids as needed only if higher risk and willing to intensify; 3. Once on optimal therapy, no need to recheck lipids routinely References 1. U.S. Department of Veterans Affairs/Department of Defense Health Executive Committee (HEC). Evidence based practice work group charter. January 9, 2017. 2. U.S. Centers for Disease Control and Prevention. Total and high-density lipoprotein cholesterol in adults: United States, 2015 2016. 2017. www.cdc.gov/nchs/products/databriefs/db290.htm. Accessed Nov 1, 2019. 3. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. Mar 3 2020;141(9):e139-e596. PMID: 31992061. 4.


Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. Mar 3 2020;141(9):e139-e596. PMID: 31992061. 4. U.S. Department of Veteran Affairs, Department of Defense. Guideline for guidelines. Veterans Health Administration, Office of Quality & Performance, Evidence Review Subgroup; Revised January 29, 2019. 5. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. Jul 2013; 66(7):726-735. PMID: 23570745. 6. Newberry SJ, Ahmadzai N, Motala A, et al. AHRQ methods for effective health care. Surveillance and identification of signals for Updating systematic reviews: Implementation and early experience. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. 7. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E. Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med. Jul 17 2007; 147(2):117-122. PMID: 17576998. 8. National Institute for Health and Care Excellence. The guidelines manual. 2012; www.nice.org.uk/article/pmg6/resources/non-guidance-the-guidelines-manual-pdf. Accessed Sep 16, 2019. 9. Martinez Garcia L, McFarlane E, Barnes S, Sanabria AJ, Alonso-Coello P, Alderson P. Updated recommendations: An assessment of NICE clinical guidelines. Implement Sci. 2014;9:72. PMID: 24919856. 10. White CM, Ip S, McPheeters M, et al. AHRQ methods for effective health care using existing systematic reviews to replace de novo processes in conducting comparative effectiveness reviews. Methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008. 11. Institute of Medicine (US) Committe on Standards for Developing Trustworthy Clinical Practice Guidelines, Graham R, Mancher M, Miller Wolman D, et al., editors. Clinical practice guidelines we can trust. Washington, DC: National Academies Press;2011. 12. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.


Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:22. PMID: 17147811. 13. U.S. Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2014; www.healthquality.va.gov/guidelines/CD/lipids/VADoDDyslipidemiaCPG2014.pdf. 14. Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. Dec 2008;20(12):600-607. PMID: 19120591. 15. Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. Sep 2000;49(9):796-804. PMID: 11032203. 16. Fiscella K, Meldrum S, Franks P, et al. Patient trust: Is it related to patient-centered behavior of primary care physicians? Med Care. Nov 2004;42(11):1049-1055. PMID: 15586831. 17. Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. Jama. Jan 9 2013;309(2):139-140. PMID: 23299601. 18. Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington DC: National Academies Press; 2001. 19. Society for Medical Decision Making Committee on Standardization of Clinical Algorithms. Proposal for clinical algorithm standards. Med Decis Making. Apr-Jun 1992;12(2):149-154. PMID: 1573982. 20. Chamnan P, Simmons RK, Sharp SJ, Khaw KT, Wareham NJ, Griffin SJ. Repeat cardiovascular risk assessment after four years: Is there improvement in risk prediction? PLoS One. 2016;11(2):e0147417. PMID: 26895071. 21. Angelow A, Schmidt CO, Dorr M, Chenot JF. Utility of repeat serum cholesterol measurements for assessment of cardiovascular risk in primary prevention. Eur J Prev Cardiol. Apr 2015;23(6):628-635. PMID: 26170419. 22. Perera R, McFadden E, McLellan J, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: A systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. Dec 2015;19(100):1-401, vii-viii. PMID: 26680162. 23. Ontario HQ.


Health Technol Assess. Dec 2015;19(100):1-401, vii-viii. PMID: 26680162. 23. Ontario HQ. Frequency of testing for dyslipidemia: An evidence-based analysis. Ont Health Technol Assess Ser. 2014;14(6):1-30. PMID: 26316920. 24. Howard G, McClure LA, Moy CS, et al. Self-Reported Stroke Risk Stratification: Reasons for geographic and racial differences in stroke study. Stroke. Jul 2017;48(7):1737-1743. PMID: 28526763. 25. Pike MM, Decker PA, Larson NB, et al. Improvement in cardiovascular risk prediction with electronic health records. J Cardiovasc Transl Res. Jun 2016;9(3):214-222. PMID: 26960568. 26. Pennells L, Kaptoge S, Wood A, et al. Equalization of four cardiovascular risk algorithms after systematic recalibration: Individual-participant meta-analysis of 86 prospective studies. Eur Heart J. Feb 14 2019; 40(7):621-631. PMID: 30476079. 27. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised Pooled Cohort Equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. Jul 3 2018; 169(1):20-29. PMID: 29868850. 28. Sussman JB, Wiitala WL, Zawistowski M, Hofer TP, Bentley D, Hayward RA. The Veterans Affairs Cardiac Risk Score: Recalibrating the atherosclerotic cardiovascular disease score for applied use. Med Care. Sep 2017; 55(9):864-870. PMID: 28763374. 29. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk factors in cardiovascular disease risk assessment: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. Jul 17 2018;320(3):281-297. PMID: 29998301. 30. Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. Jan 19 2016;67(2):139-147. PMID: 26791059. 31. Kim KP, Einstein AJ, Berrington de Gonzalez A. Coronary artery calcification screening: Estimated radiation dose and cancer risk. Arch Intern Med. Jul 13 2009;169(13):1188-1194. PMID: 19597067. 32. Novo S, Carita P, Lo Voi A, et al.


32. Novo S, Carita P, Lo Voi A, et al. Impact of preclinical carotid atherosclerosis on global cardiovascular risk stratification and events in a 10-year follow-up: Comparison between the algorithms of the Framingham Heart Study, the European SCORE and the Italian 'Progetto Cuore'. J Cardiovasc Med (Hagerstown). Feb 2019;20(2):91-96. PMID: 30557211. 33. Jonas DE, Reddy S, Middleton JC, et al. Screening for cardiovascular disease risk with resting or exercise electrocardiography: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. Jun 12 2018;319(22):2315-2328. PMID: 29896633. 34. Graversen P, Abildstrom SZ, Jespersen L, Borglykke A, Prescott E. Cardiovascular risk prediction: Can Systematic Coronary Risk Evaluation (SCORE) be improved by adding simple risk markers? Results from the Copenhagen City Heart Study. Eur J Prev Cardiol. Sep 2016;23(14):1546-1556. PMID: 26976846. 35. Natriuretic Peptides Studies C, Willeit P, Kaptoge S, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. Oct 2016;4(10):840-849. PMID: 27599814. 36. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. Apr 2019;210:18-28. PMID: 30716508. 37. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. Nov 15 2016; 316(19):2008-2024. PMID: 27838722. 38. Ponce OJ, Larrea-Mantilla L, Hemmingsen B, et al. Lipid-lowering agents in older individuals: A systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. May 1 2019;104(5):1585- 1594. PMID: 30903687. 39. Palmer SC, Navaneethan SD, Craig JC, et al.


PMID: 30903687. 39. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. May 31 2014(5):CD007784. PMID: 24880031. 40. Albert MA, Glynn RJ, Fonseca FA, et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. Jul 2011;162(1):106-114.e102. PMID: 21742096. 41. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation. Nov 25 2008;118(22):2243- 2251, 2244p following 2251. PMID: 18997194. 42. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet. Sep 30 2006;368(9542):1155-1163. PMID: 17011942. 43. Yusuf S, Bosch J, Dagenais G, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. May 26 2016;374(21):2021-2031. PMID: 27040132. 44. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dl or above: Analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. Nov 14 2017; 136(20):1878-1891. PMID: 28877913. 45. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: A meta-analysis. Drugs. Dec 24 2012;72(18):2365- 2373. PMID: 23186103. 46. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. Feb 2019;39(2):e38-e81. PMID: 30580575. 47.


Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. Feb 2019;39(2):e38-e81. PMID: 30580575. 47. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. Nov 20 2008;359(21):2195-2207. PMID: 18997196. 48. Engeda JC, Stackhouse A, White M, et al. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. Diabetes Res Clin Pract. May 2019;151:96-105. PMID: 30954511. 49. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: Systematic review and meta-analysis. BMC Med. Mar 22 2014;12:51. PMID: 24655568. 50. Nayak A, Hayen A, Zhu L, et al. Legacy effects of statins on cardiovascular and all-cause mortality: A meta- analysis. BMJ Open. Oct 4 2018;8(9):e020584. PMID: 30287603. 51. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review. Br J Clin Pharmacol. Oct 2014;78(4):684-698. PMID: 25364801. 52. Beliard S, Boccara F, Cariou B, et al. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French familial hypercholesterolemia registry. Atherosclerosis. Oct 2018;277:334- 340. PMID: 30270068. 53. Perez-Calahorra S, Laclaustra M, Marco-Benedi V, et al. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis. May 2019;284:245-252. PMID: 30827715. 54. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. Feb 2007;29(2):253-260. PMID: 17472818. 55. Li H, Wang C, Zhang S, et al. Safety profile of atorvastatin 80 mg: A meta-analysis of 17 randomized controlled trials in 21,910 participants. Drug Saf. May 2016;39(5):409-419. PMID: 26860922. 56.


Safety profile of atorvastatin 80 mg: A meta-analysis of 17 randomized controlled trials in 21,910 participants. Drug Saf. May 2016;39(5):409-419. PMID: 26860922. 56. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. Nov 13 2010;376(9753): 1670-1681. PMID: 21067804. 57. Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: A meta-analysis. Sci Rep. Jan 10 2017;7:39982. PMID: 28071756. 58. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate- dose statin therapy: A meta-analysis. JAMA. Jun 22 2011;305(24):2556-2564. PMID: 21693744. 59. Pandit AK, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K. High-dose statin therapy and risk of intracerebral hemorrhage: A meta-analysis. Acta Neurol Scand. Jul 2016;134(1):22-28. PMID: 26647879. 60. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke. Aug 2012;43(8):2149-2156. PMID: 22588266. 61. Sun H, Yuan Y, Wang P, et al. Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: A meta-analysis. Lipids Health Dis. Nov 2 2015;14:140. PMID: 26526340. 62. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: Meta- analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012; 7(1):e29849. PMID: 22276132. 63. Bytyci I, Bajraktari G, Bhatt DL, et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta- analysis of randomized controlled trials. J Clin Lipidol. May - Jun 2017;11(3):624-637. PMID: 28506385. 64.


J Clin Lipidol. May - Jun 2017;11(3):624-637. PMID: 28506385. 64. Suzuki H, Watanabe Y, Kumagai H, Shuto H. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis. Dec 2013;7(6):306-315. PMID: 24280596. 65. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and meta-analysis. Curr Med Res Opin. Jun 2011;27(6):1191-1210. PMID: 21473671. 66. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo- controlled trial. Lancet. Jun 25 2011;377(9784):2181-2192. PMID: 21663949. 67. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. Jun 18 2015;372(25):2387-2397. PMID: 26039521. 68. Du H, Li X, Su N, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: A systematic review and meta-analysis. Heart. Aug 2019;105(15):1149-1159. PMID: 30842207. 69. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. Apr 16 2015;372(16):1489-1499. PMID: 25773378. 70. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. Apr 28 2017; 4:CD011748. PMID: 28453187. 71. Korman MJ, Retterstol K, Kristiansen IS, Wisloff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. Sep 2018;36(9):1031-1041. PMID: 29777433. 72. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-effectiveness of alirocumab: A just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med. Jan 1 2019. PMID: 30597485. 73.


Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-effectiveness of alirocumab: A just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med. Jan 1 2019. PMID: 30597485. 73. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. Oct 8 2005; 366(9493):1267-1278. PMID: 16214597. 74. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet. Aug 11 2012;380(9841):581-590. PMID: 22607822. 75. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol. Feb 28 2017;69(8):911-921. PMID: 28231942. 76. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. Apr 10 2018;137(15):1571-1582. PMID: 29263150. 77. de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: A meta-analysis. PLoS One. 2014;9(11):e111247. PMID: 25372483. 78. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials. Eur Heart J. Apr 7 2018;39(14):1172-1180. PMID: 29069377. 79. Khan SU, Rahman H, Okunrintemi V, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: A systematic review and meta-analysis. J Am Heart Assoc. Apr 2 2019;8(7):e011581. PMID: 30898075. 80. Hong N, Lee YH, Tsujita K, et al.


PMID: 30898075. 80. Hong N, Lee YH, Tsujita K, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: A meta-analysis. Endocrinol Metab (Seoul). Jun 2018;33(2):219-227. PMID: 29766679. 81. Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all- cause mortality events. Cochrane Database Syst Rev. Nov 19 2018;11:CD012502. PMID: 30480766. 82. Leiter LA, Tinahones FJ, Karalis DG, et al. Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials. Diabet Med. Dec 2018;35(12):1742-1751. PMID: 30183102. 83. Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: A meta-analysis of individual patient data. Eur Heart J. Feb 1 2018;39(5):374-381. PMID: 29186504. 84. Bai J, Gong LL, Li QF, Wang ZH. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. J Clin Lipidol. Mar - Apr 2018; 12(2):277-291 e273. PMID: 29428832. 85. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: Pooled data from randomized trials. J Am Coll Cardiol. Feb 7 2017;69(5):471-482. PMID: 28153102. 86. Schwartz GG, Steg PG, Szarek M, Bhatt DL. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. Nov 29 2018;379(22):2097-2107. PMID: 30403574. 87. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. May 4 2017;376(18):1713-1722. PMID: 28304224. 88. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. Apr 8 2004;350(15):1495-1504.


Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. Apr 8 2004;350(15):1495-1504. PMID: 15007110. 89. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. Apr 7 2005;352(14):1425-1435. PMID: 15755765. 90. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients. BMJ. Jul 18 2014;349:g4379. PMID: 25038074. 91. Schandelmaier S, Briel M, Saccilotto R, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. Jun 14 2017;6:CD009744. PMID: 28616955. 92. Kaur N, Pandey A, Negi H, et al. Effect of HDL-raising drugs on cardiovascular outcomes: A systematic review and meta-regression. PLoS One. 2014;9(4):e94585. PMID: 24728455. 93. U.S. Food and Drug Administration. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed release capsules. approval-of-indications-related-to-the-coadministration-with-statins. Accessed November 1, 2019. 94. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonzalez I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. Nov 16 2016;11:CD009753. PMID: 27849333. 95. Shao K, Tang Y, Zhou D, Huang S. Comparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia: A meta-analysis. Int J Clin Exp Med. 2016 2016;9(3):5291- 5300. 96. Murray AM, Hsu FC, Williamson JD, et al. ACCORDION MIND: Results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. Jan 2017;60(1):69-80. PMID: 27766347. 97. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. Apr 29 2010;362(17):1563-1574. PMID: 20228404. 98.


N Engl J Med. Apr 29 2010;362(17):1563-1574. PMID: 20228404. 98. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. Mar 14 2019;380(11):1022-1032. PMID: 30865796. 99. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. Jan 3 2019;380(1):11-22. PMID: 30415628. 100. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. Nov 30 2018;11:CD003177. PMID: 30521670. 101. Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. Jan 7 2016(1):CD011472. PMID: 26758499. 102. Sahebkar A, Serban C, Ursoniu S, Banach M. Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition. Jan 2016;32(1):33-40. PMID: 26522661. 103. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: The AGE at Heart trial. Integr Blood Press Control. 2016;9:9-21. PMID: 26869811. 104. Zhu J, Chen H, Song Z, Wang X, Sun Z. Effects of ginger (Zingiber officinale Roscoe) on type 2 diabetes mellitus and components of the metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2018;2018:5692962. PMID: 29541142. 105. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. Aug 2014;24(8):823-836. PMID: 24675010. 106. Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. May 2019;143:1-16.


Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. May 2019;143:1-16. PMID: 30844537. 107. National Institutes of Health. Red yeast rice fact sheet. 2013; www.nccih.nih.gov/health/red-yeast-rice. Accessed April 17, 2020. 108. National Institutes of Health, Office of Dietary Supplements. Dietary supplements: What you need to know. 2011. www.ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.aspx. Accessed September 4, 2019. 109. Shin J, Chung JW, Jang HS, et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta- analysis of 23 randomised trials. Eur J Prev Cardiol. Feb 20 2019:2047487319830503. PMID: 30782002. 110. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low- density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiol. Sep 1 2018;3(9):823-828. PMID: 30073316. 111. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA. Apr 17 2018; 319(15):1566-1579. PMID: 29677301. 112. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. Sep 27 2016; 316(12):1289-1297. PMID: 27673306. 113. Cai R, Yuan Y, Zhou Y, et al. Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: A meta-analysis. PLoS One. 2014;9(8):e104922. PMID: 25122464. 114. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. Ann Intern Med. Apr 2 2013;158(7):526-534. PMID: 23546564. 115. Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: A cohort study. Ann Intern Med. Aug 15 2017;167(4):221-227. PMID: 28738423. 116. Mampuya WM, Frid D, Rocco M, et al.


PMID: 28738423. 116. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J. Sep 2013;166(3):597-603. PMID: 24016512. 117. Riaz H, Khan AR, Khan MS, et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. Sep 1 2017;120(5):774-781. PMID: 28779871. 118. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol. Apr 17 2006;97(8A):52C-60C. PMID: 16581329. 119. Kang JH, Nguyen QN, Mutka J, Le QA. Rechallenging statin therapy in Veterans with statin-induced myopathy post vitamin D replenishment. J Pharm Pract. Oct 2017;30(5):521-527. PMID: 27798247. 120. Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation. N Am J Med Sci. Mar 2015;7(3):86-93. PMID: 25838999. 121. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Cochrane corner: Interventions to improve adherence to lipid-lowering medication. Heart. Mar 2018;104(5):367-369. PMID: 29440453. 122. Fischer MA, Choudhry NK, Bykov K, et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Med Care. Dec 2014;52(12):1050-1054. PMID: 25322157. 123. Vollmer WM, Owen-Smith AA, Tom JO, et al. Improving adherence to cardiovascular disease medications with information technology. Am J Manag Care. Nov 2014;20(11 Spec No. 17):SP502-510. PMID: 25811824. 124. National Center for Health Statistics. National health expenditures, average annual percent change, and percent distribution, by type of expenditure: United States, selected years 1960 2014. Hyattsville, MD: Centers for Disease Control and Prevention; 2015. 125. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. Mar 1 2019;4(3):206-213. PMID: 30758506. 126.


Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. Mar 1 2019;4(3):206-213. PMID: 30758506. 126. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann Pharmacother. Sep 2010;44(9):1410-1421. PMID: 20702755. 127. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. Jun 1 2011;107(11):1662-1666. PMID: 21439533. 128. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. Jun 10 2015(6):CD011737. PMID: 26068959. 129. Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. Mar 13 2019;3:CD009825. PMID: 30864165. 130. Wu Y, Qian Y, Pan Y, et al. Association between dietary fiber intake and risk of coronary heart disease: A meta-analysis. Clin Nutr. Aug 2015;34(4):603-611. PMID: 24929874. 131. Academy of Nutrition and Dietetics. Medical nutrition therapy effectiveness (MNT) systematic review (2013-2015). 2015. 132. King AC, Whitt-Glover MC, Marquez DX, et al. Physical activity promotion: Highlights from the 2018 physical activity guidelines advisory committee systematic review. Med Sci Sports Exerc. Jun 2019;51(6):1340-1353. PMID: 31095090. 133. Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA. Nov 20 2018; 320(19):2020-2028. PMID: 30418471. 134. Hupin D, Roche F, Gremeaux V, et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >/=60 years: A systematic review and meta-analysis. Br J Sports Med. Oct 2015;49(19):1262-1267. PMID: 26238869. 135. Stamatakis E, Lee IM, Bennie J, et al. Does strength-promoting exercise confer unique health benefits?


Stamatakis E, Lee IM, Bennie J, et al. Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints. Am J Epidemiol. May 1 2018;187(5):1102-1112. PMID: 29099919. 136. Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: A detailed pooled analysis of the dose-response relationship. JAMA Intern Med. Jun 2015;175(6):959-967. PMID: 25844730. 137. Patel AV, Hildebrand JS, Leach CR, et al. Walking in relation to mortality in a large prospective cohort of older U.S. adults. Am J Prev Med. Jan 2018;54(1):10-19. PMID: 29056372. 138. Kamada M, Shiroma EJ, Buring JE, Miyachi M, Lee IM. Strength training and all-cause, cardiovascular disease, and cancer mortality in older women: A cohort study. J Am Heart Assoc. Oct 31 2017;6(11). PMID: 29089346. 139. Dohrn IM, Sjostrom M, Kwak L, Oja P, Hagstromer M. Accelerometer-measured sedentary time and physical activity-a 15 year follow-up of mortality in a Swedish population-based cohort. J Sci Med Sport. Jul 2018; 21(7):702-707. PMID: 29128418. 140. Gebel K, Ding D, Chey T, Stamatakis E, Brown WJ, Bauman AE. Effect of moderate to vigorous physical activity on all-cause mortality in middle-aged and older Australians. JAMA Intern Med. Jun 2015;175(6):970- 977. PMID: 25844882. 141. Schnohr P, O'Keefe JH, Lange P, Jensen GB, Marott JL. Impact of persistence and non-persistence in leisure time physical activity on coronary heart disease and all-cause mortality: The Copenhagen City Heart Study. Eur J Prev Cardiol. Oct 2017;24(15):1615-1623. PMID: 28728482. 142. Chastin SFM, De Craemer M, De Cocker K, et al. How does light-intensity physical activity associate with adult cardiometabolic health and mortality? Systematic review with meta-analysis of experimental and observational studies. Br J Sports Med. Mar 2019;53(6):370-376. PMID: 29695511. 143. Loprinzi PD, Cardinal BJ.


Br J Sports Med. Mar 2019;53(6):370-376. PMID: 29695511. 143. Loprinzi PD, Cardinal BJ. Association between biologic outcomes and objectively measured physical activity accumulated in >/= 10-minute bouts and <10-minute bouts. Am J Health Promot. Jan-Feb 2013;27(3):143- 151. PMID: 23286590. 144. Zou Z, Cai W, Cai M, Xiao M, Wang Z. Influence of the intervention of exercise on obese type II diabetes mellitus: A meta-analysis. Prim Care Diabetes. Jun 2016;10(3):186-201. PMID: 26553963. 145. Hayashino Y, Jackson JL, Fukumori N, Nakamura F, Fukuhara S. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. Dec 2012;98(3):349-360. PMID: 23116535. 146. Cui J, Yan JH, Yan LM, Pan L, Le JJ, Guo YZ. Effects of yoga in adults with type 2 diabetes mellitus: A meta- analysis. J Diabetes Investig. Mar 2017;8(2):201-209. PMID: 27370357. 147. Abell B, Glasziou P, Hoffmann T. The contribution of individual exercise training components to clinical outcomes in randomised controlled trials of cardiac rehabilitation: A systematic review and meta-regression. Sports Med Open. Dec 2017;3(1):19. PMID: 28477308. 148. Ambrosius WT, Polonsky TS, Greenland P, et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. Apr 2012;9(2):232-246. PMID: 22333998. 149. Agency for Health Research and Quality. The effective health care program stakeholder guide appendix d: Research questions & PICO(TS) 2011. https://www.ahrq.gov/research/findings/evidence-based- reports/stakeholderguide/appendixc.html. 150. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. Apr 2011;64(4):395-400. PMID: 21194891. 151. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol. Jul 2013;66(7):719-725. PMID: 23312392.


Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol. Jul 2013;66(7):719-725. PMID: 23312392. 152. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. Jun 18 2019;139(25):e1082-e1143. PMID: 30586774. 153. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. Jun 25 2019;73(24):3168-3209. PMID: 30423391. 154. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: A special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. Jun 25 2019;73(24):3153-3167. PMID: 30423392. 155. U.S. Department of Veterans Affairs. Mediterranean diet. Nutrition and Food Services 2015; www.nutrition.va.gov/docs/UpdatedPatientEd/Mediterraneandiet.pdf. Accessed April 3, 2020.


PRACTICE GUIDELINE 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Chest Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation WRITING COMMITTEE MEMBERS Clyde W. Yancy, MD, MSc, FACC, FAHA, Chairyz; Mariell Jessup, MD, FACC, FAHA, Vice Chair*y; Biykem Bozkurt, MD, PhD, FACC, FAHAy; Javed Butler, MBBS, FACC, FAHA*y; Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHAx; Mark H. Drazner, MD, MSc, FACC, FAHA*y; Gregg C. Fonarow, MD, FACC, FAHA*y; Stephen A. Geraci, MD, FACC, FAHA, FCCPk; Tamara Horwich, MD, FACCy; James L. Januzzi, MD, FACC*y; Maryl R. Johnson, MD, FACC, FAHA{; Edward K. Kasper, MD, FACC, FAHAy; Wayne C. Levy, MD, FACC*y; Frederick A. Masoudi, MD, MSPH, FACC, FAHAy#; Patrick E. McBride, MD, MPH, FACC**; John J. V. McMurray, MD, FACC*y; Judith E. Mitchell, MD, FACC, FAHAy; Pamela N. Peterson, MD, MSPH, FACC, FAHAy; Barbara Riegel, DNSc, RN, FAHAy; Flora Sam, MD, FACC, FAHAy; Lynne W. Stevenson, MD, FACC*y; W. H. Wilson Tang, MD, FACC*y; Emily J. Tsai, MD, FACCy; Bruce L. Wilkoff, MD, FACC, FHRS*yy *Writing committee members are required to recuse themselves from voting on sections to which their speci c relationships with industry and other entities may apply; see Appendix 1 for recusal information. yACCF/AHA representative. zACCF/AHA Task Force on Practice Guidelines liaison. xAmerican College of Physicians representative. kAmerican College of Chest Physicians representative. {International Society for Heart and Lung Transplantation representative. #ACCF/AHA Task Force on Performance Measures liaison. **American Academy of Family Physicians representative. yyHeart Rhythm Society representative. zzFormer Task Force member during this writing effort.


yyHeart Rhythm Society representative. zzFormer Task Force member during this writing effort. This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in May 2013. The American College of Cardiology Foundation requests that this document be cited as follows: Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:1495 539. This article has been copublished in Circulation. Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com. Permissions: Multiple copies, modi cation, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier s permission department at healthpermissions@elsevier.com. Journal of the American College of Cardiology 2013 by the American College of Cardiology Foundation and the American Heart Association, Inc.


Journal of the American College of Cardiology 2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc. ACCF/AHA TASK FORCE MEMBERS Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chairzz; Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN, FAHA; Biykem Bozkurt, MD, PhD, FACC, FAHA; Ralph G. Brindis, MD, MPH, MACC; Mark A. Creager, MD, FACC, FAHAzz; Lesley H. Curtis, PhD; David DeMets, PhD; Robert A. Guyton, MD, FACC; Judith S. Hochman, MD, FACC, FAHA; Richard J. Kovacs, MD, FACC, FAHA; Frederick G. Kushner, MD, FACC, FAHAzz; E. Magnus Ohman, MD, FACC; Susan J. Pressler, PhD, RN, FAAN, FAHA; Frank W. Sellke, MD, FACC, FAHA; Win-Kuang Shen, MD, FACC, FAHA; William G. Stevenson, MD, FACC, FAHAzz; Clyde W. Yancy, MD, MSc, FACC, FAHAzz TABLE OF CONTENTS Preamble 1497 1. Introduction 1499 1.1. Methodology and Evidence Review 1499 1.2. Organization of the Writing Committee 1499 1.3. Document Review and Approval 1499 1.4. Scope of This Guideline With Reference to Other Relevant Guidelines or Statements 1500 2. De nition of HF 1500 3. HF Classi cations 1500 4. Epidemiology 1501 5. Initial and Serial Evaluation of the HF Patient: Recommendations 1502 5.1. Clinical Evaluation 1502 5.1.1. History and Physical Examination 1502 5.1.2. Risk Scoring 1503 5.2. Diagnostic Tests 1503 5.3. Biomarkers 1503 5.4. Noninvasive Cardiac Imaging 1504 5.5. Invasive Evaluation 1505 6. Treatment of Stages A to D: Recommendations 1505 6.1. Stage A 1505 6.2. Stage B 1505 6.3. Stage C 1506 6.3.1. Nonpharmacological Interventions 1506 6.3.2. Pharmacological Treatment for Stage C HFrEF 1506 6.3.3. Pharmacological Treatment for Stage C HFpEF 1510 6.3.4. Device Therapy for Stage C HFrEF 1510 6.4. Stage D 1513 6.4.1. Water Restriction 1513 6.4.2.


Device Therapy for Stage C HFrEF 1510 6.4. Stage D 1513 6.4.1. Water Restriction 1513 6.4.2. Inotropic Support 1513 6.4.3. Mechanical Circulatory Support 1516 6.4.4. Cardiac Transplantation 1516 7. The Hospitalized Patient: Recommendations 1516 7.1. Precipitating Causes of Decompensated HF 1517 7.2. Maintenance of GDMT During Hospitalization 1517 7.3. Diuretics in Hospitalized Patients 1517 7.4. Renal Replacement TherapydUltra ltration 1518 7.5. Parenteral Therapy in Hospitalized HF 1518 7.6. Venous Thromboembolism Prophylaxis in Hospitalized Patients 1518 7.7. Arginine Vasopressin Antagonists 1518 7.8. Inpatient and Transitions of Care 1518 8. Important Comorbidities in HF 1519 Interventional Treatments of HF: Recommendations 1519 10. Coordinating Care for Patients With Chronic HF: Recommendations 1520 11. Quality Metrics/Performance Measures: Recommendations 1520 12. Evidence Gaps and Future Research Directions 1520 References 1522 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 1533 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 1536 Yancy et al. JACC Vol. 62, No. 16, 2013 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary October 15, 2013:1495 539 Preamble The medical profession should play a central role in evalu- ating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the bene ts and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist clinicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a founda- tion for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.


Moreover, clinical practice guidelines can provide a founda- tion for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools. The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guide- lines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evalu- ating all available evidence to develop balanced, patient- centric recommendations for clinical practice. Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-speci c data and write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing commit- tees are asked to perform a literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected outcomes where such data exist. Patient-speci c modi ers, comorbid- ities, and issues of patient preference that may in uence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on ef cacy and outcomes constitute the primary basis for the recommendations contained herein. In analyzing the data and developing recommendations and supporting text, the writing committee uses evidence-based methodologies developed by the Task Force (1). The Class of Recommendation (COR) is an estimate of the size of the treatment effect considering risks versus bene ts in addition to evidence and/or agreement that a given treatment or procedure is or is not useful/effective or in some situations may cause harm. The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect.


The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect. The writing committee reviews and ranks evidence supporting each recommendation with the weight of evidence ranked as LOE A, B, or C according to speci c de nitions that are included in Table 1. Studies are identi ed as observational, retrospective, prospective, or randomized where appropriate. For certain conditions for which inadequate data are available, recommendations are based on expert consensus and clinical experience and are ranked as LOE C. When recommendations at LOE C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues for which sparse data are available, a survey of current practice among the clinicians on the writing committee is the basis for LOE C recommendations and no references are cited. The schema for COR and LOE are summarized in Table 1, which also provides suggested phrases for writing recommendations within each COR. A new addition to this methodology is separation of the Class III recommendations to delineate whether the recommendation is determined to be of no bene t or is associated with harm to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another have been added for COR I and IIa, LOE A or B only. In view of the advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force has designated the term guideline-directed medical therapy (GDMT) to represent optimal medical therapy as de ned by ACCF/AHA guidelinerecommended therapies (primarily Class I). This new term, GDMT, will be used herein and throughout all future guidelines.